FLX Bio, Inc. (Series C)
Funding Details
Awarder
Inbox
Date Award
December 21, 2017
Vertical
Immuno-oncology
Funding Amount
$60,000,000
Company Info
Market
Cancer treatment
Location
San Francisco, CA, USA
Coinvestors
Celgene Corporation, The Column Group, Topspin Partners
Company Description

FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio's small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment.

Links